BMY Bristol-Myers Squibb Company

45.77
+0.09  (+0%)
Previous Close 45.68
Open 45.81
Price To Book 4.92
Market Cap 74,867,115,903
Shares 1,635,724,621
Volume 24,456,514
Short Ratio 7.48
Av. Daily Volume 14,079,509

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 1H 2020.
CM-649 – Opdivo+ Yervoy or Chemo
Gastric cancer
Phase 2 data April 25, 2019 did not meet primary endpoints.
CM-714 Opdivo + Yervoy
First-line Head and Neck Cancer
Phase 1/2 updated melanoma data June 1, 2019 noted ORR was 53% (34% CR);.
NKTR-214 + OPDIVO (nivolumab) - PIVOT-2
Urothelial carcinoma, Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers
Late-breaker at SITC November 11, 2017. ORR 14-32%.
BMS-986205 and Nivolumab
Advanced tumors
Phase 2 ongoing. Abstract presented at ASCO June 2018.
Opdivo and Rubraca
Castration-resistant prostate cancer (mCRPC)
Phase 3 trial planned.
Opdivo and Rubraca
Triple-negative breast cancers
Phase 3 enrolment has commenced - noted August 8, 2018.
Opdivo and Rubraca ATHENA
Ovarian Cancer - First-line maintenance treatment
Approval announced March 6, 2018.
Opdivo - 4 week applications
Approval announced November 10, 2017.
Sprycel (dasatinib)
Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia
Approval announced July 6, 2017.
ORENCIA
Psoriatic Arthritis (PsA)
Phase 1/2 preliminary data presented at ASCO June 2, 2017. ORR=21%.
CM-358 – Opdivo
Cervical, vaginal and vulvar cancers
Phase 1/2 ORR rate of 12.5% noted at ASCO June 3, 2017.
BMS-986016 - LAG-3 + Opdivo
Melanoma
Phase 3 trial initiated mid-2017. Data from Phase 1/2 at ASH 2017 showed a 83% ORR and 62% CR.
ADCETRIS and Opdivo CM-812
Relapsed Hodgkin Lymphoma
Approved under priority review September 22, 2017.
Opdivo (CM-040)
Previously Treated Hepatocellular Carcinoma
Phase 2 data due 2018.
TG4010 and Opdivo
Non-squamous non-small cell lung cancer (NSCLC)
Phase 2 late breaker at ASCO June 5, 2017. Control rate 44%. ORR 19%.
Opdivo + Yervoy
Malignant pleural mesothelioma (MPM)
Phase 1/2 initiated April 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-207)
Solid tumors
Phase 1/2 trial enrolling. Oral presentation at ASCO June 5, 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-204)
Solid tumors
Approval announced August 1, 2017.
CM-142 – Opdivo
(dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC)
Phase 3 first overall survival (OS) positive data released April 3, 2017
CM - 067 Opdivo in combination with Yervoy
Melanoma
Phase 3 data due early 2020.
CABOMETYX (cabozantinib) with Opdivo and Yervoy - CheckMate 9ER
First-line renal cell carcinoma
Phase 3 data released January 19, 2017.
Opdivo - ONO-4538-12
Gastric cancer
Phase 2 presentation at AACR Meeting April 16, 2018.
CM-568 - Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 3 data due 1H 2020.
CM-651 – Opdivo + Yervoy
First-line Head and Neck Cancer
Phase 3 trial did not meet primary endpoint - June 24, 2019.
CM-459 – Opdivo
First-line Hepatocellular carcinoma (HCC) - cancer
Phase 3 ongoing.
CM-511 – Opdivo + Yervoy
First-line Melanoma
Phase 3 trial did not meet primary endpoint - November 26, 2018.
CM-451 – Opdivo + Yervoy
First-line Small cell lung cancer (SCLC)
Phase 3 data released October 12, 2018 - primary endpoint not met.
CM-331– Opdivo
Second-line Small cell lung cancer (SCLC)
Phase 3 interim data released June 6, 2017 - primary endpoint met. Data presented at ESMO September 10, 2017 - HR 0.65 compared to Yervoy. FDA Approval announced December 20, 2017.
CM-238 – Opdivo (Adjuvant)
Melanoma
Approved April 16, 2018.
CM-214 – Opdivo + Yervoy
First-line Renal cell carcinoma (RCC)
Phase 3 data due summer 2019.
CM-227 – Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 3 data released April 3, 2017 - primary endpoint not met.
CM-143 – Opdivo
Second-line Glioblastoma (GBM) cancer
Phase 3 trial met primary endpoint - November 30, 2017.
CM-078 – Opdivo
Second-line Non-small cell lung cancer (NSCLC)
Urothelial Carcinoma - Bladder cancer
Opdivo (nivolumab)
Bladder cancer
Approval announced July 11, 2018.
CM-142 – Opdivo
(dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC)
FDA approval announced August 17, 2018.
CM-32 - Opdivo+chemo
Small cell lung cancer (SCLC)
Phase 3 clinical hold lifted June 1, 2018.
CM-602 – Opdivo + pomalidomide and dexamethasone
Multiple Myeloma
FDA approval announced November 6, 2018.
Empliciti (elotuzumab) - ELOQUENT-3
Relapsed/refractory multiple myeloma
FDA Approval announced January 2, 2019.
Sprycel (dasatinib)
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Phase 2 trial to be initiated 2Q 2019.
IPI-549 + Nivolumab (MARIO-275)
Urothelial cancer
Phase 3 data due 1H 2020.
CM-648 Opdivo + Yervoy
Esophageal Cancer
Phase 3 data due 1H 2020.
CM-901 Opdivo + Yervoy
Urothelial Cancer
Phase 3 data due 2020.
CM-274 Opdivo (nivolumab)
Bladder cancer
Phase 3 data due 2020.
CM-577 - Opdivo
Esophageal cancer
Phase 3 data due 2H 2019.
CM-743 Opdivo + Yervoy
Mesothelioma
Phase 3 data due 2020.
Opdivo (nivolumab) and Ipilimumab (Yervoy) CM-915
Melanoma
Phase 3 data due 2H 2019.
CM-548 - Opdivo
First-line Glioblastoma (GBM) cancer
Phase 3 data due 2022.
CM-914 Opdivo in combination with Yervoy
Renal Cell Carcinoma
Phase 3 data due 2020.
CM-9LA Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 3 data released May 9, 2019 did not meet primary endpoint.
CM-498 Opdivo
Phase 3 data due 2H 2019.
Phase 3 trial initiation announced May 1, 2019.
Cabozantinib and Nivolumab and Ipilimumab (COSMIC-313)
Renal Cell Carcinoma
Phase 2 presentation at EHA June 15, 2019.
ADCETRIS and Opdivo CM-744
Relapsed/Refractory Classical Hodgkin Lymphoma